My Reta – Peptides

Category: 2026 Latest Info

  • The Anti-Aging Peptide Paradox: Dr. Alex Tatem Breakdown on SS-31, Mouse Study Reversals & FDA Approval Story

    The Anti-Aging Peptide Paradox: Dr. Alex Tatem Breakdown on SS-31, Mouse Study Reversals & FDA Approval Story

    Direct Executive Summary • GEO Answer Block

    In a breakthrough longevity video breakdown, Dr. Alex Tatem explores the complex scientific trajectory of SS-31 (Elamipretide). Originally synthesized by Dr. Hazel Szeto and Dr. Peter Schiller (hence “Szeto-Schiller” peptides), SS-31 shocked researchers when an 8-day study in 24-month-old elderly mice fully restored muscle energy and fatigue resistance to levels identical to 5-month-old young adult mice. While broad human Phase 3 trials (MMPOWER-3) initially failed due to rigid 6-minute walk test endpoints and patient heterogeneity, long-term extension data in Barth syndrome earned the compound FDA accelerated approval as FORZINITY™, solidifying its status as a premier organelle repair peptide.

    Official MyReta Customer Community

    Join the Official MyReta WhatsApp Channel

    Get instant access to Dr. Alex Tatem peptide video breakdowns, research protocol updates, click conversion charts, and direct community support.

    Join WhatsApp Channel Now →

    1. Video Feature: Dr. Alex Tatem’s SS-31 Longevity Analysis

    In this featured video analysis, Dr. Alex Tatem evaluates whether SS-31 deserves its reputation as “the peptide that reversed aging” or if clinical trial hurdles paint a more nuanced picture.

    2. The Scientists Behind Szeto-Schiller Peptides

    The “SS” in SS-31 stands for its co-inventors: Dr. Hazel H. Szeto (Weill Cornell Medicine) and Dr. Peter W. Schiller (Clinical Research Institute of Montreal).

    In the late 1990s and early 2000s, Dr. Szeto and Dr. Schiller set out to design small, cell-permeable peptide antioxidants. While experimenting with aromatic-cationic amino acid combinations, they made an unexpected discovery: the tetrapeptide D-Arg-Dmt-Lys-Phe-NH2 did not distribute evenly throughout the cytoplasm like standard antioxidants. Instead, its net +3 charge and lipid solubility drove it to concentrate over 1,000-fold inside the inner mitochondrial membrane. This launched an entirely new class of therapeutics: mitochondria-targeted organelle repair peptides.

    3. The Shocking 8-Day Mouse Study That Reversed Muscle Aging

    One of the most remarkable milestones in SS-31 research was a landmark study conducted at the University of Washington (published by Marcinek et al. in Aging Cell).

    Key Study Findings (Old Mice vs. Young Mice):

    • Experimental Subjects: 24-to-27-month-old elderly mice (equivalent to 70–80-year-old humans) exhibiting severe age-related sarcopenia and mitochondrial decay.
    • Treatment Duration: Only 8 days of continuous SS-31 administration.
    • Resulting Bioenergetics: Maximum mitochondrial ATP production rate ($\text{ATP}_{\text{max}}$) and muscle fatigue resistance in the aged mice increased back to levels statistically indistinguishable from 5-month-old young mice.
    • Mechanism of Recovery: The rapid restoration occurred without any increase in muscle mass or mitochondrial volume, proving that SS-31 restored functional mitochondrial quality and respiratory coupling efficiency.

    4. Why Human Phase 3 Trials (MMPOWER-3) Failed Primary Endpoints

    Despite overwhelming preclinical data, SS-31 hit a major bottleneck during Phase 3 human clinical trials (the MMPOWER-3 trial for Primary Mitochondrial Myopathy). The trial failed to achieve statistically significant improvement over placebo in its primary endpoint—the 6-minute walk test (6MWT).

    Why Did Human Trials Miss? Dr. Alex Tatem Pinpoints 3 Core Reasons:

    1. Rigid Endpoint Selection: The 6-minute walk test is heavily influenced by systemic factors, motivation, and acute joint discomfort, making it a noisy metric for measuring microscopic cellular membrane stabilization.
    2. Extreme Genetic Heterogeneity: Primary Mitochondrial Myopathy comprises dozens of distinct nuclear and mitochondrial DNA mutations. Grouping highly diverse genetic pathologies into a single trial masked subgroup efficacy.
    3. Acute vs. Chronic Intervention Windows: Short 12-to-24 week trial windows were insufficient to capture the slow, structural remodeling of human tissue compared to rapid rodent metabolic turnover.

    5. How SS-31 Won FDA Approval (FORZINITY™)

    Recognizing that broad myopathy trials missed owing to design flaws, developer Stealth BioTherapeutics pivoted to Barth Syndrome—a specific, ultra-rare X-linked genetic disorder caused by TAZ gene mutations that destroy cardiolipin synthesis.

    By analyzing long-term open-label extension cohorts over 3 years (SPIBA-001) against external natural history controls, researchers demonstrated dramatic, durable gains in cardiac stroke volume, muscle strength, and reduced hospitalization rates. In late 2024 / 2025, the U.S. FDA granted accelerated approval for FORZINITY™ (elamipretide hydrochloride), validating SS-31 as a approved treatment for cardiolipin-deficient mitochondrial disease.

    Research Phase Study Model Observed Result Clinical Significance
    Preclinical Discovery In Vitro Cardiolipin Binding 1,000x IMM enrichment; inhibits cytochrome c peroxidase Proved targeted cardiolipin binding mechanism
    Preclinical Aging Study 24-Month Aged Mice (8 Days) Full restoration of ATP output & fatigue resistance to 5-mo levels Demonstrated rapid functional organelle rejuvenation
    Phase 3 Clinical Trial MMPOWER-3 (Myopathy) Missed 6-minute walk test primary endpoint vs placebo Highlighted trial design flaws in heterogeneous groups
    FDA Accelerated Approval Barth Syndrome (FORZINITY™) Statistically significant cardiac & muscle strength gains vs controls First FDA-approved mitochondrial cardiolipin therapy

    6. Dr. Alex Tatem’s Medical Verdict & Real-World Longevity Dosing

    Dr. Alex Tatem concludes that SS-31 is not an anabolic peptide for rapid muscle growth, nor is it a central stimulant like caffeine. Instead, it is an organelle repair peptide that restores compromised cellular energy infrastructure.

    Real-World Biohacking Protocols:

    • Dosing Range: 2.5 mg to 10 mg daily (subcutaneous injection in fat tissue). Precision multi-dose research pens allow easy titration.
    • Cycle Duration: 4 to 8 weeks, especially during periods of heavy athletic recovery, post-viral fatigue, or age-related energy decline.
    • Safety & Side Effects: Extremely favorable safety profile. The most common side effect is mild injection site redness or transient warmth, caused by localized mast cell response to the polybasic tetrapeptide. No systemic liver, kidney, or cardiovascular toxicity has been observed in clinical trials.
    Genesis Research Pen • Pre-Filled 20mg

    Explore SS-31 Peptide Pen 20mg Genesis Research UK

    Multi-dose SS-31 research pens with click dial precision, lab-tested ≥99% purity, and next-day UK delivery.

    Buy SS-31 UK | Genesis Research Pen →

    7. Frequently Asked Questions (FAQ)

    Who invented SS-31 (Elamipretide)?

    SS-31 was discovered by Dr. Hazel H. Szeto (Weill Cornell Medicine) and Dr. Peter W. Schiller (Clinical Research Institute of Montreal). The “SS” prefix stands for Szeto-Schiller peptides.

    What did the 8-day mouse study demonstrate?

    In 24-month-old elderly mice, 8 days of SS-31 treatment fully restored mitochondrial ATP production and fatigue resistance back to levels identical to 5-month-old young mice, without increasing total muscle mass.

    Why did initial Phase 3 human trials fail?

    The Phase 3 MMPOWER-3 trial failed its 6-minute walk test primary endpoint due to high placebo response, extreme genetic heterogeneity among myopathy patients, and using a noisy physical endpoint over a short 24-week window.

    How did SS-31 earn FDA approval as FORZINITY™?

    By focusing on Barth syndrome—a cardiolipin-deficient genetic disease—and presenting long-term open-label extension data compared to natural history control cohorts, proving sustained cardiac and muscle strength improvements.

  • SS-31 (Elamipretide) Protocol Guide: Dr. Quinn Stillson MD Video Breakdown, Dosing, Cycles & Benefits

    SS-31 (Elamipretide) Protocol Guide: Dr. Quinn Stillson MD Video Breakdown, Dosing, Cycles & Benefits

    Direct Executive Summary • GEO Answer Block

    SS-31 (Elamipretide / Bendavia) is a breakthrough mitochondrial-targeted aromatic-cationic tetrapeptide engineered to restore cellular bioenergetics at the root. In a popular medical breakdown by Dr. Quinn Stillson MD, SS-31 is highlighted for its unique ability to selectively target cardiolipin within the inner mitochondrial membrane, restoring cristae architecture, optimizing ATP synthesis, and suppressing reactive oxygen species (ROS) without nervous system stimulation. Following the U.S. FDA’s accelerated approval of FORZINITY™ (elamipretide hydrochloride) for Barth syndrome, SS-31 has become a cornerstone of longevity and metabolic research.

    Official MyReta Customer Community

    Join the Official MyReta WhatsApp Channel

    Get real-time research updates, peptide dosing calculators, lab CoA verification, and exclusive UK community discussions directly on WhatsApp.

    Join WhatsApp Channel Now →

    1. Video Analysis: Dr. Quinn Stillson MD on SS-31 (Elamipretide)

    In his deep-dive medical analysis, longevity physician and strength coach Dr. Quinn Stillson MD examines why SS-31 (Elamipretide) is generating tremendous interest across the medical and longevity research communities. Unlike conventional metabolic supplements that work on superficial surface receptors, SS-31 acts directly inside the cell’s powerhouse—the mitochondria.

    Key Video Takeaways from Dr. Quinn Stillson MD:

    • Mitochondrial Repair at the Source: SS-31 specifically binds to cardiolipin, a unique phospholipid in the inner mitochondrial membrane, preventing ROS-induced lipid peroxidation and restoring energy production efficiency.
    • FDA Recognition & Approval: Highlighted the clinical transition of elamipretide to FDA-approved drug status (FORZINITY™) for Barth syndrome, validating decades of biophysical research.
    • Non-Stimulatory Energy Boost: Increases baseline ATP output without triggering CNS jitters, heart rate spikes, or adrenal stress associated with traditional stimulants.
    • Practical Dosing & Stacking: Explains effective research dosages, administration frequency, cycle lengths, and how SS-31 fits into a 2-step protocol alongside MOTS-c.

    2. Molecular Mechanism of Action: Targeting Cardiolipin

    To understand why Dr. Stillson emphasizes SS-31, one must look at how mitochondria generate energy. The inner mitochondrial membrane (IMM) relies heavily on a specialized phospholipid called cardiolipin to maintain structural folding (cristae) and assemble respiratory supercomplexes (Complex I, III, IV, and ATP Synthase).

    As cells age or suffer from oxidative stress, reactive oxygen species (ROS) degrade cardiolipin. This causes the inner membrane cristae to unfold, leading to electron leakage, reduced ATP production, and systemic cellular fatigue.

    The SS-31 Cardiolipin Cascade:

    1. Selective Membrane Penetration: With a net +3 positive charge and amphipathic structure (D-Arg-Dmt-Lys-Phe-NH2), SS-31 rapidly concentrates in the inner mitochondrial membrane.
    2. Cardiolipin Electrostatic Binding: SS-31 binds tightly to negatively charged cardiolipin phosphate heads while its aromatic groups intercalate into acyl chains.
    3. Cristae Structural Restoration: Re-establishes microdomain lipid packing, tightening cristae curvature and respirasome coupling.
    4. ROS Inhibition & ATP Boost: Halts cytochrome c peroxidase activity, suppressing oxidative stress by 30%–50% while accelerating ATP resynthesis.

    3. Dosing Guidelines, Frequency & Cycle Protocols

    As highlighted in Dr. Quinn Stillson’s video, researchers and medical professionals employ structured dosing protocols when evaluating SS-31.

    Standard Research Dosages

    • Micro-Dose Titration: 0.25 mg to 1.0 mg daily (subcutaneous injection). Utilizing precision multi-dose pens (such as the Genesis 20mg Pen), 4 clicks equal 250 mcg (0.25 mg) and 16 clicks equal 1.0 mg.
    • Standard Clinical Protocol: 2.5 mg to 5.0 mg daily subcutaneously for general cellular bioenergetic maintenance and post-exercise recovery.
    • Intensive Repair Protocol: 10 mg daily subcutaneously (often split into morning and early afternoon administration).

    Administration Frequency & Timing

    SS-31 possesses a short systemic half-life but establishes durable biophysical effects within mitochondrial membranes. Subcutaneous administration in the morning with fat (abdominal region) ensures smooth tissue distribution. Because SS-31 is non-stimulatory, it does not disrupt sleep architecture.

    Cycle Duration

    Dr. Stillson recommends evaluating SS-31 in 4-week to 8-week cycles. Common protocols involve a 30-day continuous acute mitochondrial repair phase followed by a 2-to-4 week washout period or transition to metabolic signaling peptides like MOTS-c.

    Genesis Research Pen • Pre-Filled 20mg

    Source SS-31 Peptide Pen 20mg (Genesis Research UK)

    Pre-filled SS-31 20mg multi-dose pens featuring precision click dial calibration, lab-tested ≥99% purity, and next-day UK delivery.

    Buy SS-31 UK | Genesis Research Pen →

    4. The 2-Step ‘Mitochondrial Reset Protocol’ (SS-31 + MOTS-c)

    A key highlight from Dr. Stillson’s analysis is how SS-31 synergizes with other mitochondrial peptides, specifically MOTS-c.

    Protocol Phase Target Peptide Dose & Frequency Primary Objective
    Phase 1 (Days 1–20) SS-31 (Elamipretide) 2.5mg – 5.0mg Subcutaneous Daily Repair existing cristae, rebuild cardiolipin, and lower ROS oxidative burden.
    Phase 2 (Days 21–40) MOTS-c Peptide 5mg Subcutaneous 2x–3x Weekly Trigger AMPK activation, insulin sensitivity, and new mitochondrial biogenesis.

    Attempting to stimulate new mitochondrial growth (via MOTS-c) while existing organelles remain structurally compromised is inefficient. Phase 1 (SS-31) fixes the structural foundation before Phase 2 (MOTS-c) expands mitochondrial volume.

    5. Clinical Indications & Regulatory Status

    Dr. Stillson highlights several therapeutic domains where SS-31 has demonstrated profound clinical efficacy:

    • Barth Syndrome (FDA Approved FORZINITY™): Genetic cardioskeletal disorder caused by tafazzin mutations. SS-31 restores muscle strength, cardiac stroke volume, and physical capacity in long-term clinical trials.
    • Ischemia-Reperfusion & Acute Kidney Injury (AKI): Preserves renal tubular cell polarity and reduces infarct area by 30%–40% following oxygen deprivation.
    • Dry Age-Related Macular Degeneration (Geographic Atrophy): ReCLAIM-2 trials demonstrated a 43% reduction in macular ellipsoid zone attenuation.
    • Cardiovascular Health & Sarcopenia: Boosts left ventricular ejection fraction and mitigates age-related muscle decline.

    Never Miss a UK Peptide Research Breakdown

    Join hundreds of UK researchers and fitness enthusiasts in the official MyReta WhatsApp Community for daily scientific insights, pen click math guides, and live support.

    Join Official WhatsApp Channel →

    6. Frequently Asked Questions (FAQ)

    What is the primary benefit of SS-31 according to Dr. Quinn Stillson MD?

    Dr. Stillson highlights SS-31’s ability to repair mitochondrial cristae by binding cardiolipin, boosting cellular ATP energy output and reducing oxidative stress without activating central nervous system stimulants or adrenaline.

    How do I join the MyReta WhatsApp Customer Channel?

    You can join the official customer WhatsApp channel directly by visiting https://whatsapp.com/channel/0029VbDYM5c9xVJdgkjWsE3c. Members receive research protocol updates, dosage calculators, and direct community support.

    What is the recommended injection frequency for SS-31?

    SS-31 is typically administered subcutaneously once daily in the morning over a 4-to-8 week cycle.

    How does SS-31 compare to MOTS-c?

    SS-31 focuses on structural repair of existing mitochondrial inner membranes and cardiolipin (“fixing the engine”), whereas MOTS-c signals nuclear gene expression to stimulate new mitochondrial creation and systemic glucose regulation (“building more engines”).

  • Retatrutide TRIUMPH Results: Phase 3 Weight-Loss & Diabetes Data (2026)

    Retatrutide TRIUMPH Results: Phase 3 Weight-Loss & Diabetes Data (2026)

    Retatrutide just posted the biggest weight-loss numbers of any obesity drug tested so far. In 2026 its large Phase 3 trials — the TRIUMPH programme and the TRANSCEND-T2D diabetes study — finally gave us the proper, regulator-grade data everyone had been waiting years for. Here’s what the trials actually showed, in plain English, with the figures checked against Eli Lilly’s own releases and The Lancet.

    On this page

    Key takeaways

    • TRIUMPH-1 showed 28.3% mean weight loss at 80 weeks on the 12 mg dose, versus 2.2% on placebo.
    • 45.3% of people on 12 mg lost 30% or more of their body weight — the highest proportion ever reported for a weight-loss medicine.
    • People with a higher starting BMI who carried on to 104 weeks lost an average of 30.3% (about 85 lb).
    • TRANSCEND-T2D-1 cut HbA1c by up to 1.94% and body weight by up to 16.8% in type 2 diabetes, published in The Lancet.
    • Retatrutide still has no MHRA or FDA approval — these are trial results, and in the UK it remains a research compound for laboratory use only.

    What retatrutide is (the “triple agonist” bit)

    Retatrutide (lab code LY3437943) is what scientists call a triple agonist. That sounds like a wrestling move, but it just means the drug switches on three different hunger-and-metabolism receptors at once — GLP-1, GIP, and glucagon — instead of one or two. Semaglutide (Wegovy) hits one. Tirzepatide (Mounjaro) hits two. Retatrutide goes for the full set, like someone who can’t walk past a buy-one-get-one-free sign.

    For years the only data came from a small Phase 2 trial. That changed in 2026, when the big Phase 3 results landed — the kind regulators actually look at. (New to the compound? Start with what retatrutide actually is.)

    TRIUMPH-1: the headline obesity trial

    TRIUMPH-1 enrolled 2,339 adults with obesity, or overweight plus a weight-related health problem, but no diabetes. They were given retatrutide at 4 mg, 9 mg, or 12 mg, or a placebo (a dummy dose used for comparison), once a week for 80 weeks. Eli Lilly announced the topline results on 21 May 2026.

    DoseMean weight loss at 80 weeks
    4 mg19.0%
    9 mg25.9%
    12 mg28.3%
    Placebo2.2%

    The number that made headlines: 45.3% of people on the 12 mg dose lost 30% or more of their body weight — territory previously seen mostly after weight-loss surgery, and the highest share ever reported for an anti-obesity drug. A jab doing a job once reserved for an operating theatre.

    It kept going, too. Participants with a higher baseline BMI who stayed on 12 mg through 104 weeks lost an average of 30.3% of their body weight — around 85 lb.

    For rough context, tirzepatide came in around 20–22.5% and semaglutide 2.4 mg around 14.9% in their own Phase 3 obesity trials. Different trials with different people, so it isn’t a perfectly fair race — but the trend is clear. For a plain-English look at the numbers on their own, see our retatrutide weight-loss results guide.

    TRANSCEND-T2D-1: retatrutide and type 2 diabetes

    A separate trial, TRANSCEND-T2D-1, tested retatrutide in 537 adults who do have type 2 diabetes and whose blood sugar wasn’t controlled by diet and exercise alone. Over 40 weeks it:

    • cut HbA1c (a marker of average blood sugar over months) by 1.69% to 1.94% across the doses, versus 0.81% on placebo;
    • cut body weight by 11.5% to 16.8%, versus 2.5% on placebo.

    The results were published in The Lancet in June 2026 — the medical world’s equivalent of getting your name in lights.

    The wider TRIUMPH programme: knee and sleep apnoea

    TRIUMPH isn’t a single trial. It’s a family of Phase 3 studies that began in 2023 and has enrolled more than 5,800 participants, testing retatrutide not just for weight but for the conditions that extra weight causes:

    • Knee osteoarthritis (TRIUMPH-4). People with obesity and knee OA on 12 mg lost an average of 28.7% of body weight at 68 weeks, and knee-pain scores (WOMAC) dropped by up to 75.8%.
    • Obstructive sleep apnoea (a substudy within TRIUMPH-1). Among participants with severe sleep apnoea, the apnoea-hypopnoea index fell by 60.6% from a severe baseline — a big improvement in overnight breathing.

    If those benefits hold up, retatrutide starts to look less like a weight-loss drug with nice side effects and more like a treatment for the diseases that excess weight drives in the first place.

    ADA 2026 and where approval stands

    The TRIUMPH-1 and TRANSCEND-T2D-1 data were presented at the American Diabetes Association’s 86th Scientific Sessions on 6 June 2026 — think of it as the World Cup of diabetes research, just with more lanyards and fewer penalty shoot-outs.

    Worth saying plainly: retatrutide still doesn’t have MHRA or FDA approval. Phase 3 is the stage before approval, not after it. These are trial results, not a green light to prescribe it. In the UK it remains available only as a research compound for laboratory use — not for human consumption — until a regulator says otherwise. If you need lab-tested retatrutide for research, see our UK retatrutide range, all supplied with a batch-specific Certificate of Analysis.

    Frequently asked questions

    What did the retatrutide TRIUMPH-1 trial find?

    In 2,339 adults with obesity and no diabetes, retatrutide produced mean weight loss of 28.3% at 80 weeks on the 12 mg dose, versus 2.2% on placebo. 45.3% of 12 mg participants lost 30% or more of their body weight, and those with a higher baseline BMI who continued to 104 weeks lost an average of 30.3%.

    How does retatrutide compare to Mounjaro and Wegovy?

    Retatrutide is a triple agonist (GLP-1, GIP and glucagon), whereas tirzepatide/Mounjaro is a dual agonist and semaglutide/Wegovy is a single GLP-1 agonist. In their respective Phase 3 obesity trials tirzepatide reached roughly 20–22.5% and semaglutide 2.4 mg about 14.9%, compared with retatrutide’s 28.3% at 12 mg — though these are separate trials and not head-to-head.

    What did TRANSCEND-T2D-1 show?

    In 537 adults with type 2 diabetes, over 40 weeks retatrutide reduced HbA1c by up to 1.94% and body weight by up to 16.8%, versus 0.81% and 2.5% on placebo. The results were published in The Lancet in June 2026.

    Is retatrutide approved in the UK?

    No. It has no MHRA or FDA marketing authorisation. TRIUMPH and TRANSCEND are Phase 3 trial results, not a regulatory approval. In the UK retatrutide is supplied only as a research compound for laboratory use, not for human consumption.

    What is the TRIUMPH programme?

    A family of Phase 3 trials that began in 2023 and has enrolled more than 5,800 participants, testing retatrutide for weight management and related conditions including knee osteoarthritis (TRIUMPH-4) and obstructive sleep apnoea (a TRIUMPH-1 substudy), with further results expected.

    Related retatrutide reading

    Final thoughts

    The 2026 data is genuinely significant: the largest Phase 3 weight-loss numbers published to date, plus real improvements in blood sugar, knee pain and sleep apnoea. It’s still investigational, and nothing here is medical advice — but for anyone following the science, retatrutide has clearly raised the bar.

    For the full breakdown of retatrutide’s published weight-loss data, see our clinical trial results guide. If you’re sourcing retatrutide for research purposes, browse our UK retatrutide range and always check for a batch-specific, third-party Certificate of Analysis confirming ≥99% purity — see our quality testing page for how we verify stock.

    This article is for informational and research purposes only and reports published clinical-trial data. Retatrutide is an investigational compound with no MHRA or FDA marketing authorisation, supplied for laboratory research use only and not for human consumption. Nothing here is medical advice.

  • Retatrutide Weight Loss Results: What the Clinical Trials Actually Show (2026)

    Retatrutide Weight Loss Results: What the Clinical Trials Actually Show (2026)

    Retatrutide produced a mean weight reduction of up to 24.2% over 48 weeks in Eli Lilly’s Phase 2 trial — and, unusually, the weight loss had not plateaued when the study ended. That single fact is why retatrutide (LY3437943) is currently the most talked-about compound in obesity research. This guide lays out exactly what the retatrutide weight loss results show, where the numbers come from, how it stacks up against semaglutide and tirzepatide, and the all-important UK research context. To understand the wider class context of what do peptides do in research, check out our plain-English guide. No hype — just the published data, accurately.

    On this page

    Key takeaways

    • Up to 24.2% mean body-weight reduction at the 12 mg dose over 48 weeks (Phase 2), versus roughly 2.1% on placebo.
    • That’s around 26 kg on average — and the curve was still falling at week 48, with no clear plateau.
    • It’s a triple agonist (GLP-1 + GIP + glucagon) — the glucagon arm is what sets it apart from semaglutide and tirzepatide.
    • It remains investigational: no MHRA or FDA marketing authorisation, and in the UK it’s supplied only as a research compound.
    • Phase 3 (TRIUMPH) is ongoing and will decide its clinical future.

    What is retatrutide?

    Retatrutide (development code LY3437943) is a once-weekly injectable peptide developed by Eli Lilly. It’s described as a “triple agonist” because it activates three metabolic receptors at once:

    • GLP-1 (glucagon-like peptide-1) — curbs appetite, slows gastric emptying
    • GIP (glucose-dependent insulinotropic polypeptide) — supports insulin response and appetite control
    • Glucagon receptor — the differentiator, linked to increased energy expenditure and fat metabolism

    Semaglutide (Wegovy/Ozempic) hits one of those receptors; tirzepatide (Mounjaro/Zepbound) hits two. Retatrutide hits all three — the mechanistic reason its trial numbers run higher.

    The headline weight-loss results

    The pivotal data come from the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023): 338 adults with obesity, randomised to retatrutide (1, 4, 8 or 12 mg) or placebo, for 48 weeks.

    • 12 mg dose: −24.2% mean body weight at 48 weeks — roughly 26 kg.
    • 8 mg dose: around −22%.
    • Placebo: approximately −2.1%.
    • No plateau: at the highest doses the weight curve was still declining at week 48 — meaning the 24.2% may understate the full effect over a longer period.

    That last point is what excited researchers most: most weight-loss agents flatten out, but retatrutide hadn’t. You can read the primary data in the NEJM Phase 2 publication. (For comparison, the “28.7%” figure floating around some sites isn’t the headline published mean — the robust, citable number is 24.2% at 48 weeks.)

    How retatrutide drives weight loss

    The triple mechanism works on three fronts at once:

    • Appetite regulation — the GLP-1 and GIP activity reduces hunger signalling and increases satiety, so less food is eaten without constant willpower.
    • Energy expenditure — the glucagon component is associated with increased fat metabolism and higher metabolic activity, in theory burning more rather than only eating less.
    • Blood-sugar control — improved glucose handling and reductions in HbA1c were seen in trial participants.

    It’s the glucagon arm — absent from semaglutide and tirzepatide — that researchers credit for the extra edge.

    Beyond weight: liver fat and metabolic health

    The results that arguably impressed clinicians most weren’t on the scales. In the trial, retatrutide was associated with dramatic reductions in liver fat, with a large proportion of participants who had fatty liver (steatosis) reaching normal liver-fat levels. Improvements in blood pressure, lipids and insulin sensitivity were also reported.

    This is the angle urologist Dr Alex Tatem highlighted on The Diary of a CEO when he described an unreleased compound that “tortures belly fat at a disproportionate rate” while delivering “the best improvements we’ve ever seen in… liver health” — predicting a “trillion-dollar drug when it comes out.” The visceral-fat-and-liver profile of retatrutide fits that description closely. (Our full breakdown of his interview is here.)

    Retatrutide vs semaglutide vs tirzepatide

    Approximate mean weight-loss figures from each compound’s pivotal trials:

    CompoundReceptor targetsApprox. mean weight loss
    Semaglutide (Wegovy)GLP-1~15% (STEP trials, 68 wks)
    Tirzepatide (Mounjaro/Zepbound)GLP-1 + GIP~20–22.5% (SURMOUNT)
    RetatrutideGLP-1 + GIP + glucagon~24.2% (Phase 2, 48 wks, still falling)

    A direct caveat for honesty: these come from different trials of different lengths and populations, so they’re indicative, not a head-to-head. But the trend — more receptors, more effect — is consistent.

    Phase 3: the TRIUMPH programme

    Retatrutide is now in Phase 3 trials (the TRIUMPH programme), the stage that evaluates long-term safety and effectiveness across much larger populations and decides whether it reaches the market. Until those complete and a regulator grants authorisation, retatrutide remains an investigational compound — promising data, not an approved medicine.

    Side effects in the trial

    Like other metabolic peptides, the side-effect profile was mostly gastrointestinal and dose-dependent:

    • Nausea, vomiting, diarrhoea and general GI discomfort were the most common.
    • Effects were more frequent at higher doses and during dose escalation.
    • Some participants discontinued over tolerability.

    Gradual dose titration was used to limit these — a standard approach across the GLP-1 class.

    The UK research context

    This is the part the hype tends to skip. Retatrutide has no MHRA marketing authorisation and no FDA approval — it is still in clinical trials. In the UK it cannot legally be sold or prescribed as a weight-loss medicine. What UK suppliers offer is retatrutide as a research compound, for laboratory use only — not for human consumption.

    So when you read “retatrutide weight loss results,” you’re reading clinical trial outcomes from Eli Lilly’s controlled studies — not a claim about a product you can buy and use. If you’re sourcing it for research, the only thing that separates a credible supplier from a risky one is verification: a batch-specific, third-party Certificate of Analysis confirming identity and ≥99% purity (see our quality testing page). Researchers handling lyophilised vials can work out exact concentrations with our free retatrutide reconstitution calculator.

    Frequently asked questions

    How much weight did people lose on retatrutide?

    In Eli Lilly’s Phase 2 trial, the 12 mg dose produced a mean reduction of about 24.2% of body weight over 48 weeks (roughly 26 kg), versus around 2.1% on placebo — and the loss had not plateaued by the study’s end.

    Is retatrutide better than tirzepatide or semaglutide?

    On trial averages, retatrutide’s ~24% exceeds tirzepatide’s ~20–22% and semaglutide’s ~15%, largely thanks to its added glucagon activity. But these are separate trials, and Phase 3 head-to-head data will tell the fuller story.

    Is retatrutide approved or available in the UK?

    No. It’s investigational, with no MHRA authorisation, and is supplied in the UK only as a research compound — not for human consumption.

    Does retatrutide help with fatty liver?

    Trial data showed substantial reductions in liver fat, with many participants who had steatosis reaching normal liver-fat levels — one of the most notable findings beyond weight loss.

    What are the main side effects?

    Predominantly gastrointestinal — nausea, vomiting and diarrhoea — and dose-dependent, which is why trials used gradual dose escalation.

    Final thoughts

    Retatrutide’s Phase 2 numbers — ~24.2% mean weight loss in 48 weeks, still falling, with striking liver-fat improvements — are why it’s described as potentially the most powerful obesity compound in development. The honest framing matters too: it’s investigational, the Phase 3 results aren’t in, and in the UK it’s a research compound only. If you’re researching it, start with verification — see current lab-tested stock on our retatrutide UK page, or the per-vial detail for Retaklik (Retatrutide) 60mg and Retatrutide 2.0 (45mg).

    Source: Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023.

    This article is for informational and research purposes only and reports published clinical-trial data. Retatrutide is an investigational compound supplied for laboratory research use only and is not for human consumption. It has no MHRA or FDA marketing authorisation. Nothing here is medical advice.